Concurrent Investment Advisors LLC Has $3.24 Million Stake in Novartis AG $NVS

Concurrent Investment Advisors LLC grew its position in Novartis AG (NYSE:NVS) by 39.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,676 shares of the company’s stock after purchasing an additional 5,843 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Novartis were worth $3,240,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Archer Investment Corp raised its stake in Novartis by 93.0% during the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after buying an additional 80 shares during the last quarter. Evolution Wealth Management Inc. boosted its position in Novartis by 552.0% during the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after acquiring an additional 138 shares during the last quarter. Atlatl Advisers LLC bought a new stake in Novartis during the second quarter valued at $26,000. CrossGen Wealth LLC acquired a new stake in Novartis during the 4th quarter worth about $28,000. Finally, Bank of Jackson Hole Trust raised its position in shares of Novartis by 425.0% in the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 187 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVS has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $141.20.

More Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reaffirmed its sales guidance through 2030 following the del-desiran trial setback, limiting concerns that the disappointing result will materially affect near-term revenue expectations. Novartis announces trial setback on del-desiran drug
• Positive Sentiment: Investors still see potential in remibrutinib, Novartis’ multiple-sclerosis candidate. Bank of America estimates the drug could generate about $3 billion in annual peak MS sales, although regulatory approval and market-share execution remain key risks. Novartis has a potential $3 billion MS opportunity

Novartis Stock Performance

NVS opened at $159.95 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46. The company has a market cap of $305.21 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 3.12 and a beta of 0.45. The company’s fifty day moving average price is $155.79 and its two-hundred day moving average price is $153.67.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. On average, analysts expect that Novartis AG will post 8.84 EPS for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.